Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

Question and Methods: This open-label multicenter trial was the first head-to-head trial examining Ticagrelor vs Prasugrel as part of DAPT in ACS requiring angiography.

Findings: The authors found that patients taking Prasugrel had lower risk of MI, CVA, and death at one year in comparison to Ticagrelor (9.3% vs 6.9%, HR 1.36, 95% CI 1.09 – 1.70, P = 0.006). There were no differences in bleeding between the drugs.

Limitations: The main limitation of this trial is the open-label nature of the design.

Interpretation: This paper gives evidence that DAPT with ASA and Prasugrel is superior to DAPT with ASA and Ticagrelor. Due to the differences in effect size with STEMI vs NSTEMI and between timing of drugs, more studies are needed to delineate the best treatment strategy.

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

Mission Statement

World-Class Emergency Medicine: To provide outstanding compassionate emergency care through practice-changing research and innovative medical education. For more about our department, visit us at EMOttawa.